Χώρα: Νότια Αφρική
Γλώσσα: Αγγλικά
Πηγή: South African Health Products Regulatory Authority (SAHPRA)
Hexal
INDICATIONS [/za_1234.html#1] [/za_1234.html#1] [/za_1234.html#1] CONTRA-INDICATIONS [/za_1234.html#1] [/za_1234.html#1] DOSAGE [/za_1234.html#1] [/za_1234.html#1] SIDE-EFFECTS [/za_1234.html#1] [/za_1234.html#1] [/za_1234.html#1] PREGNANCY [/za_1234.html#1] [/za_1234.html#1] OVERDOSE [/za_1234.html#1] IDENTIFICATION [/za_1234.html#1] [/za_1234.html#1] PATIENT INFORMATION HEXAL-LISINOPRIL™ CO 10 TABLETS HEXAL-LISINOPRIL™ CO 20 TABLETS SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): HEXAL-LISINOPRIL™ CO 10 TABLETS HEXAL-LISINOPRIL™ CO 20 TABLETS COMPOSITION HEXAL-LISINOPRIL CO 10: Each tablet contains 10 mg LISINOPRIL (as the dihydrate) and 12,5 mg HYDROCHLOROTHIAZIDE . HEXAL-LISINOPRIL CO 20: Each tablet contains 20 mg lisinopril (as the dihydrate) and 12,5 mg hydrochlorothiazide. PHARMACOLOGICAL CLASSIFICATION: A 7.1.3 Other hypotensives. PHARMACOLOGICAL ACTION: Lisinopril/HCT is a combination of an angiotensin converting enzyme inhibitor, lisinopril and a diuretic, hydrochlorothiazide. Both these components have been widely used alone and in combination for the treatment of hypertension due to additive effects. Lisinopril is a peptidyl dipeptidase inhibitor and inhibits the angiotensin converting enzyme (ACE) that catalyses the conversion of angiotensin I to angiotensin II. Angiotensin II is a vasoconstrictor peptide which also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased concentrations of angiotensin II which results in decreased vasopressor activity and reduced aldosterone secretion. Reduced aldosterone secretion may result in an increase in serum potassium concentration. The mechanism of action through which lisinopril lowers blood pressure is mainly via suppression of the renin- angiotensin-aldosteron Διαβάστε το πλήρες έγγραφο